Search
Theravance Biopharma Inc
TBPHAdd to Watchlist
17.030USD
0.0000.00%
Close 09-23 16:00（ET）
882.66MMarket Cap
7.47P/E TTM
Theravance Biopharma Inc (TBPH) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Theravance Biopharma Inc in the past month.
Hold
0 Strong Buy
1 Buy
4 Hold
0 Sell
0 Strong Sell
Target Price
17.667USD+3.62%
TBPH Analyst Recommendation Trends
In the current month, TBPH has received 1 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. TBPH average Analyst price target in the last month is 17.667.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
1
1
2
2
2
1
1
1
2
2
3
3
3
3
4
4
3
4
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
6
7
7
7
7
6
TBPH Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, TBPH EPS is projected to reach 0.157 in FY2026Q3, following reported EPS of -0.114 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
1.22
-0.14
0.05
0.16
1.72
Actual
1.20
-0.10
-0.11
--
--
Surprise
-1.60%
+32.88%
-328.30%
--
--
FAQs
What is Theravance Biopharma Inc's expected revenue for the next quarter?
Theravance Biopharma Inc's expected revenue is 21.36M.
What is Theravance Biopharma Inc's price target?
Analysts forecast that Theravance Biopharma Inc's price target is USD 17.67, with the highest forecast at USD 19.00 and the lowest forecast at USD 17.00.
How have Theravance Biopharma IncTBPH's recent earnings per share performed?
The market expectation was USD -0.11, while Theravance Biopharma IncTBPH's earnings per share (EPS) for the previous quarter was USD -0.10. EPS for the next quarter is expected at USD 0.16.
What is the analyst rating for Theravance Biopharma Inc?
Based on the ratings of Theravance Biopharma Inc's stock from 5 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.